Latest Innovation News

Aeeris Ltd reported solid growth in Q2 FY25, driven by increased annual recurring revenue and new contracts across key sectors, while unveiling a promising new technology set to expand its market footprint.

Ramsay Health Care announces key leadership departures and a strategic realignment aimed at strengthening its core Australian hospital business and accelerating transformation under CEO Natalie Davis.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.

Weebit Nano has solidified its position in the semiconductor memory sector by signing a major licensing agreement with onsemi and raising A$50 million in capital. The company is well-funded and advancing multiple commercial and technical milestones.

Volt Group Limited reported a robust 20% increase in FY24 revenue receipts, driven by strong EcoQuip growth and strategic contract wins, while advancing its zero-emission ATEN technology with promising trials underway.

Carnegie Clean Energy has secured significant funding and made key progress in its ACHIEVE Programme, setting the stage for CETO wave energy deployment in the Basque Country in 2025.

Titomic Limited has secured AUD 30 million in equity funding and appointed new leadership as it establishes a U.S. headquarters in Huntsville, Alabama, aiming to capitalize on growing aerospace and defense demand.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

First Graphene Limited reports a robust December quarter with new patents, expanded distribution networks, and advancing commercial trials, positioning the company on a path to cash breakeven.